疫苗前沿 | 预防老年人严重呼吸道疾病效力为80%，杨森RSV疫苗达到2b期临床终点

   

参考资料：

[1] Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults. Retrieved October 3, 2021, from https://www.janssen.com/janssen-announces-start-phase-3-trial-investigational-respiratory-syncytial-virus-rsv-vaccine-older

[2] Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults. Retrieved October 3, 2021, from https://www.prnewswire.com/news-releases/janssen-announces-phase-2b-data-demonstrating-its-investigational-rsv-adult-vaccine-provided-80-protection-against-lower-respiratory-infections-in-older-adults-301391246.html

来源：药明康德